Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11261587 | 0.79 | CSNK1E (0.31) | FLT3TLR7CSNK1E | |
| SCHEMBL8240168 | 0.76 | CSNK1E (0.33) | FLT3TLR7CSNK1E | |
| SCHEMBL2179909 | 0.76 | FLT3 (0.32) | FLT3CSNK1E | |
| SCHEMBL15088571 | 0.76 | TLR7 (0.32) | TLR7 | |
| SCHEMBL14668767 | 0.76 | CSNK1E (0.30) | CSNK1E | |
| SCHEMBL25080099 | 0.76 | GRIN2D (0.33) | CSNK1E | |
| SCHEMBL18248843 | 0.72 | HCRTR2 (0.32) | — | |
| SCHEMBL20294418 | 0.72 | HCRTR1 (0.32) | — | |
| SCHEMBL7321101 | 0.71 | GRIN2D (0.34) | — | |
| SCHEMBL20912777 | 0.71 | HDAC8 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617798-B2 | Imidazopyrazne derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4161931-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-20230203047-A1 | NOVEL IMIDAZOPYRAZNE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203043-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203043-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203043-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203047-A1 | NOVEL IMIDAZOPYRAZNE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203047-A1 | NOVEL IMIDAZOPYRAZNE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20180370973-A1 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-12-27 | — | — | US | disclosed |
| WO-2016101119-A1 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106106-A2 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106106-A2 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20130303532-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20130303532-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20130303532-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| EP-2651948-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | Bayer Intellectual Property GmbH (DE) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080229-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080229-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370973-A1 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | FLT3 2020/4885TLR7 2080/4885CSNK1E 3386/4885 |
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | XDH, MYD88, IKZF3 | FLT3 141/4885TLR7 186/4885CSNK1E 302/4885 |
| US-20130303532-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | TK1, CDKL1, CDK1 | FLT3 84/4885TLR7 3698/4885CSNK1E 102/4885 |
| US-12617798-B2 | Imidazopyrazne derivatives | CLIC1, HCFC1, CXCR1 | FLT3 2144/4885TLR7 565/4885CSNK1E 91/4885 |
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | IKZF3, RRP15, IK | FLT3 66/4885TLR7 142/4885CSNK1E 594/4885 |
| US-20230203047-A1 | NOVEL IMIDAZOPYRAZNE DERIVATIVES | RPS4X, PYM1, RPS4Y1 | FLT3 279/4885TLR7 107/4885CSNK1E 388/4885 |
| US-20230203043-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IKZF3, INTS9, CYP2C9 | FLT3 128/4885TLR7 71/4885CSNK1E 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.